Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
No Thumbnail Available
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
Q: Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone? Evidence-based answer: Yes. Monthly extended-release injectable naltrexone (XR-NTX) treats opioid use disorder as effectively as daily sublingual buprenorphine-naloxone (BUP-NX) without causing any increase in serious adverse events or fatal overdoses. (strength of recommendation: A, 2 good-quality RCTs).
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.